Merck Sharp + Dohme Corp.

Lalanthi Dilrukshi Vitharana

M Arshad Siddiqui

Umar Faruk Mansoor

Lianyun Zhao

Panduranga Adulla P Reddy

Shuyi Tang

Duan Liu

Amit K Mandal

Matthew H Daniels

Andrew J McRiner

Zhaoyang Meng

Chaoyang Dai

David Benjamin Belanger

Mehul F Patel

Patrick J Curran

Liping Yang

Yang Nan

Angie R Angeles

Andrew Mcriner

Matthew Hersh Daniels

The present invention provides Pyrazolopyrimidine Compounds of Formula (I): wherein L, T, Z, U, V, W, R, R, R, R, and m are as defined herein, and pharmaceutically acceptable salts of such Pyrazolopyrimidine Compounds. The Pyrazolopyrimidine Compounds are useful in the treatment of cancer and other diseases or disorders wherein mTOR is deregulated.

Pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors

The present invention relates to certain pyrazolo[1,5-a]pyrimidine compounds of Formula (I) as inhibitors of mammalian Target Of Rapamycin (mTOR) kinase, which is also known as FRAP, RAFT, RAPT or SEP. The compounds may be used in the treatment of cancer and other disorders where mTOR is deregulated. The present invention further provides pharmaceutical compositions comprising the pyrazolo[1,5-a]pyrimidine compounds.

Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors

Growing community of inventors

Somerville, MA, United States of America

Lalanthi Dilrukshi Vitharana